Healthcare Industry News:  BoneScalpel 

Devices Surgery Distribution

 News Release - May 20, 2008

Misonix Announces Distribution Agreement for SonaStar(TM) and BoneScalpel(TM)

FARMINGDALE, N.Y.--(HSMN NewsFeed)--Misonix, Inc. (NASDAQ: MSON ), a developer of minimally invasive ultrasonic medical device technology for the ablation of cancer and other chronic health conditions, today announced that it has entered into a three year exclusive distribution and service agreement with privately-held MD International, Inc., of Miami, Florida, for the distribution of the SonaStar™ Ultrasonic Surgical Aspiration System and the BoneScalpel™, a bone cutting device. The agreement provides MD International with the right to sell in Latin America and includes minimum purchase requirements. To date, four SonaStar systems have been shipped to Chile through MD International prior to executing this agreement.

In addition to its headquarters in Miami, MD International has operating units or sales offices in Argentina, Brazil, Chile, Colombia, Mexico, Panama, and Puerto Rico. MD International, founded in 1987, is one of the largest distributors of high tech medical equipment to Latin America and the Caribbean.

The SonaStar system allows physicians to perform the delicate, selective removal of tumors or other abnormal tissue while sparing vessels as much as possible. In addition, the system is capable of performing precise bone shaving (shaping) and is compatible with most electrocautery devices - controlling bleeding during certain surgical procedures. BoneScalpel is a new Ultrasonic Osteotome (or bone cutting device) for use in orthopedic and neurological applications related to the spine and cranium.

“Misonix is proud to partner with MD International, one of the largest distributors of high tech medical equipment to Latin America and the Caribbean,” said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. “MD International has an excellent reputation and a strong track record in successfully introducing state-of-the art medical devices to their customers. By utilizing teams of highly trained professionals who provide product knowledge, expertise and support to their customers, MD International is a recognized leader among healthcare professionals. Our relationship is off to a solid start with the shipment of four Sonastar systems prior to this agreement and we believe this agreement is a strong step forward in our strategy to achieve greater market recognition of our advanced medical device products throughout the region.”

About MD International

MD International is known as the leading exporter of medical equipment to Latin America and the Caribbean. It was founded in 1987 by James "Al" Merritt with the long-term vision of improving healthcare in the emerging markets. With more than thirty major exclusive medical manufacturers, MD supports over 600 partners and sells its products to international agencies such as the World Health Organization, UNICEF and the Pan American Health Organization. MD International’s categories cover specialties in the areas of general medicine, ENT obstetrics/ gynecology, ophthalmology, physical therapy, cardiology, surgery, critical care, anesthesiology and imaging. These units are staffed by teams of highly trained professionals who provide product knowledge, expertise and support to customers in the Latin American and Caribbean regions. For more information about MD International, visit

About Misonix:

Misonix, Inc. (NASDAQ: MSON ) designs, develops, manufactures and markets therapeutic ultrasonic medical devices and laboratory equipment. Misonix’s therapeutic ultrasonic platform is the basis for several innovative medical technologies. Misonix has a minority equity position in Focus Surgery, Inc., which uses high intensity focused ultrasound technology to destroy deep-seated cancerous tissues without affecting surrounding healthy tissue. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix’s proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company’s Web site at

With the exception of historical information contained in this press release, content herein may contain “forward looking statements” that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company’s business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.

Source: Misonix

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.